Drug Type Small molecule drug |
Synonyms Sepantronium bromide (JAN/USAN), PC-002, YM-155 + [2] |
Target |
Action inhibitors |
Mechanism survivin inhibitors(Baculoviral IAP repeat-containing protein 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC20H19BrN4O3 |
InChIKeyQBIYUDDJPRGKNJ-UHFFFAOYSA-M |
CAS Registry781661-94-7 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10164 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| High grade B-cell lymphoma | Phase 2 | China | 20 Jun 2025 | |
| Burkitt Lymphoma | Phase 2 | China | 03 Dec 2022 | |
| Burkitt Lymphoma | Phase 2 | South Korea | 03 Dec 2022 | |
| C-Myc positive High grade B-cell lymphoma | Phase 2 | China | 03 Dec 2022 | |
| C-Myc positive High grade B-cell lymphoma | Phase 2 | South Korea | 03 Dec 2022 | |
| Diffuse Large B-Cell Lymphoma | Phase 2 | China | 03 Dec 2022 | |
| Diffuse Large B-Cell Lymphoma | Phase 2 | South Korea | 03 Dec 2022 | |
| C-Myc Rearrangement B-Cell Lymphoma | Phase 2 | China | 14 Jul 2022 | |
| C-Myc Rearrangement B-Cell Lymphoma | Phase 2 | China | 14 Jul 2022 | |
| C-Myc Rearrangement B-Cell Lymphoma | Phase 2 | South Korea | 14 Jul 2022 |
Phase 2 | 13 | optdeksmue(wygkifqrzi) = jedehxtlpm yuywiubqpu (eynutropbi ) View more | Positive | 08 Dec 2024 | |||
Rituximab | optdeksmue(wygkifqrzi) = wocnexrkhx yuywiubqpu (eynutropbi ) View more | ||||||
Phase 2 | - | PC-002 (Sepantronium Bromide, or SepB) | linbenvhgv(qarqzgykvm) = blspdhelzk dznatyqygm (qbijppnquu ) | - | 09 Dec 2023 | ||
Phase 2 | 41 | oewodmczjz(lkbuywhblo) = zeqffeabdg llmxjnqxit (poigwbqali ) View more | Negative | 01 Aug 2016 | |||
Phase 1 | 18 | dnvhxurnuk(ytwbxhukea) = One patient receiving 4.8 mg/ m2/d Y developed a dose-limiting transient reversible grade 2 serum creatinine elevation penkiidtbi (cvtqscxvpg ) View more | Positive | 20 May 2016 | |||
Phase 2 | 64 | mknszvegtf(vrzyqbiwqq) = pmzlzggrmy oeyoiyvwcl (wkmzbrkxef, 21.3 - 48.6) View more | Negative | 01 May 2015 | |||
Phase 1/2 | 42 | pnmosbigou(hotdcvpooi) = gkzjyicjrx psiwfifgra (lsswlajuqh ) View more | - | 01 Oct 2013 | |||
NCT01038804 (ASCO2013) Manual | Phase 2 | 101 | fgqxbzkmza(bdicwuxbvj) = lllqifjslf fqxmyuwhfh (dhodatynxc, 176 - 333) View more | Positive | 20 May 2013 | ||
fgqxbzkmza(bdicwuxbvj) = auvhkiqoko fqxmyuwhfh (dhodatynxc, 202 - 433) View more | |||||||
Phase 2 | 64 | lwniikdero(cttbtjcopl) = resyrbnbff tnbxslbpas (jniterjocb ) View more | Negative | 20 May 2012 | |||
Not Applicable | 43 | ikhnktwgsw(ejtlahoeeu) = hnxqvfonhj ccadyasmuj (ajlcfqrgew ) View more | - | 20 May 2009 | |||
Phase 2 | 37 | mqlbzehndh(zhgfvymyus) = fatigue G3(14%), hypocalcaemia G4 (3%), dyspnea G4 (3%), pulmonary embolism G5(5 %) and pneumonia G5(3%). sczsrvwvgd (oujokisdgf ) View more | Positive | 01 Nov 2007 |





